Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.
about
Glycosyltransferases and non-alcoholic fatty liver diseaseMolecular changes in hepatic metabolism and transport in cirrhosis and their functional importanceDrug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma PatientsPopulation Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitisBisphenol A sulfonation is impaired in metabolic and liver diseaseMolecular Interactions between NAFLD and Xenobiotic Metabolism.Citrus flavonoid, naringenin, increases locomotor activity and reduces diacylglycerol accumulation in skeletal muscle of obese ovariectomized mice.Can paracetamol (acetaminophen) be administered to patients with liver impairment?Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis.Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.Altered Hepatic Transport by Fetal Arsenite Exposure in Diet-Induced Fatty Liver Disease.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenDownregulation of sulfotransferase expression and activity in diseased human livers.A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver diseaseAcetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Effect of Disease Pathologies on Transporter Expression and Function.Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment.Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge.Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers.Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease
P2860
Q26764913-8B31DE92-8282-4F9D-A5CC-A5E894B5B41CQ26769609-41696C52-DD42-4DD3-A6CA-BD8C2ED601F3Q28547457-74B034AA-156D-426C-8986-EB788B0DCE94Q33729768-C2C8309D-88B6-4304-BD13-AF14DC73EA65Q35085125-BDE28C14-7EB3-45EB-A5B3-86F8DB364BD9Q35102604-D4C08B8D-AC9E-44BA-A463-4398D043E96AQ35156418-43704DF9-FD3F-4CC7-A662-B30813ECB062Q35600259-18868693-7ABA-438C-911C-3A33A2D8C779Q35689076-DE4ADC12-8747-42A8-A562-E4638D1249E3Q35842935-F5B6CE87-FD34-43FF-BF49-5D2A3BD4725FQ36495243-8D05B9E8-5F5E-49A5-B73D-7B780F4BD8D3Q36549795-B75533D2-C457-40F2-8784-CAA081DC4AC1Q36679809-0576E08C-03F9-4CBD-B718-B66CC581296DQ36802077-9D97E599-9D59-4867-B844-4EF5AD56F934Q37004604-5ECB2CE7-93FA-42A7-860A-65512963F44EQ37026910-FC654923-C80B-40A4-890E-6488332CCFB3Q37083454-1C123B96-AD36-43B7-80A9-06444B9AF073Q37279407-8179FBB1-F3CF-4400-A13B-F70678025C70Q37422741-ED4ECBC3-F03A-4EA1-B8E0-394AECDDCFA4Q37669842-8BE6CB1B-04BF-4ADC-B6B1-03547037C13AQ38191681-53376C13-A49C-417A-8C3C-3F4419155D47Q38376713-12434DAA-363A-4449-835E-C36FE962E672Q38386709-6CE6AC16-F49A-4A83-B788-38C07201687BQ38737633-61C05AE8-8164-49A5-A8FC-3365637DC680Q38888360-5B7C510D-4A2C-46D7-A016-48D2179EC335Q39015474-D321A903-58D1-44A2-B367-08415DED45A4Q39111404-450BEB14-7131-464C-8FA5-37761E0009C9Q39336170-38EAF083-585B-4E55-B59C-26471ED230ADQ39413692-D3D5F4A8-B95D-4D7F-93CB-7A82CF495BAFQ40619709-1D40122A-784D-416A-81D4-0BFD0D2C5BFBQ41727130-7BB2835D-89B3-4645-A54B-D3F01C139A02Q42208301-5895534F-ABF0-4137-AE98-DB48700E96F2Q47584564-36732950-9862-4862-ABEF-BC59222FB9EDQ47847406-37CEA7B4-9C79-40B9-94DC-1EF2FE0248C4Q57559177-A5484BDB-BB16-4CBB-B327-AADA03155209
P2860
Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@ast
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@en
type
label
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@ast
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@en
prefLabel
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@ast
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@en
P2093
P2860
P356
P1476
Altered UDP-glucuronosyltransf ...... alcoholic fatty liver disease.
@en
P2093
Angela L Slitt
April D Lake
Daniel W Ferreira
Jose E Manautou
Nathan J Cherrington
Rhiannon N Hardwick
Vijay R More
Zhenqiang Lu
P2860
P304
P356
10.1124/DMD.112.048439
P577
2012-12-07T00:00:00Z